Oncology Institute, Inc.
About Oncology Institute, Inc.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $502.7M
- Net income
- -$60.6M
- Total assets
- $164.7M
- Market cap
- $486.9M
- Operating margin
- -7.2%
- Net margin
- -12.1%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $502.7M
- Operating expenses
- $538.8M
- Operating income
- -$36.1M
- Income tax
- -$131.0K
- Net income
- -$60.6M
- EPS (basic)
- $-0.54
- EPS (diluted)
- $-0.54
Balance sheet
- Total assets
- $164.7M
- Current assets
- $112.7M
- Total liabilities
- $180.4M
- Current liabilities
- $71.0M
- Shareholders’ equity
- -$15.7M
Cash flow
- Operating cash flow
- -$24.6M
- Investing cash flow
- -$3.1M
- Financing cash flow
- $11.6M
- Net cash flow
- -$16.1M
Statements via Polygon.io (SEC filings)
- Market cap
- $486.9M
- EPS (diluted)
- $-0.54
- Shares outstanding
- 96.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 15, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $60.6M in FY2025.
- Revenue grew 148% from FY2021 to FY2025.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Oncology Institute, Inc..
Write a review
News about Oncology Institute, Inc.
News & sentiment via Polygon.io
